Open AccessAdalimumab in ulcerative colitis: Two cases of mucosal healing and clinical response at two years
Author(s) -
Manuel Barreirode Acosta,
Aurelio Lorenzo,
J. Enrique Domínguez–Muñoz
Publication year - 2009
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.15.3814
Subject(s) - ulcerative colitis , medicine , adalimumab , infliximab , concomitant , adverse effect , gastroenterology , rescue therapy , vedolizumab , surgery , tumor necrosis factor alpha , disease
Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe ulcerative colitis (UC). In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC. We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years. Both patients received concomitant immunosuppressive treatment. Long term clinical remission and mucosal healing are described.